Cite
HARVARD Citation
Genovese, M. et al. (2014). THU0133 Results from A Phase 2A, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of Jnj-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Antirheumatic Drug Therapy. Annals of the rheumatic diseases. pp. 224-225. [Online].